



Duke Cancer Institute

Presented by the Duke Cancer Network
In Collaboration with the Duke Cancer Institute

Navigating Immunotoxicities from Cancer Therapies

March 17, 2023

Registration

Register online at <https://bit.ly/NavImmuno23>

Contact/Questions If you are interested in exhibiting at this conference, please contact Beth Tanner at 919-971-3627 or beth.tanner@duke.edu

Presented by the Duke Cancer Network
In Collaboration with the Duke Cancer Institute

Navigating Immunotoxicities from Cancer Therapies

March 17, 2023



Duke Cancer Institute

Description:

Immunotherapeutic approaches to cancer treatment use a patient's own immune system to target cancer cells. The side effects associated with traditional treatment options such as chemotherapy and radiation make immunotherapeutic options appealing. The immune system can identify cancer cells in one of two ways: by recognizing tumor-specific antigens or mutations, or by recognizing tumor associated antigens. Immunotherapy offers effective treatment options for cancer that offer long-lasting effects with improved overall survival and treatment tolerance. Immunotherapy can also cause organ specific toxicities or immune related adverse events. The recognition of these toxicities and their management is forefront for the clinicians caring for the oncology patient. The Duke Cancer Institute Center for Immunotherapy and the Duke Cancer Network are partnering to utilize a multidisciplinary team of oncology and immunology experts and researchers to educate on immunotoxicities occurring in cancer patients as well as management for these toxicities.

Objectives:

- Identify common immune related adverse events seen from the use of cancer immunotherapeutic agents
- Recognize various immunotoxicities effect on specific organ systems
- Examine organ-specific clinical cases, diagnostic tests and current guidelines used to guide management and treatment of the patient experiencing an immune-related adverse event

Joint Accreditation Statement



In support of improving patient care, the Duke University Health System Department of Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

Credit Statement

Physicians: Duke University Health System Department of Clinical Education and Professional Development designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nursing: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 7 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Pharmacists: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 7 ACPE credit hours. Universal Activity Numbers: JA0000655-0000-23-128-Lo4-P/T.



JOINT ACCREDITATION
INTERPROFESSIONAL CONTINUING EDUCATION

Disclaimer: The information provided at this activity is for continuing medical education purposes only and is not meant to substitute the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Course Directors

Afreen Shariff, MD, MBBS
Assistant Professor of Medicine
Director, Duke Endo-Oncology Program
Associate Director
Multi-Disciplinary Toxicity Program
DCI Center for Cancer Immunotherapy

Linda Sutton, MD
Associate Chief Medical Officer
Duke Network Services
Professor of Medicine
Duke University Health System

Duke Faculty

Meenal Kheterpal, MD
Assistant Professor of Dermatology

Michel Khouri, MD
Associate Professor of Medicine

David Ortiz-Melo, MD
Assistant Professor of Medicine

Suma Shah, MD
Assistant Professor of Neurology

Momen Wahidi, MD
Professor of Medicine

Sophia Weinmann, MD
Assistant Professor of Medicine

Honored Guest Faculty

Michael Dougan, MD, PhD
Assistant Professor of Medicine
Massachusetts General Hospital
Harvard Medical School

Jon McDunn, PhD
Executive Director
Project Data Sphere

Kerry Reynolds, MD
Clinical Director, Inpatient Oncology Units
Director, Severe Immunotherapy
Complications Service
Massachusetts General Hospital

Yousuf Zafar, MD
Senior Vice President, Medical Informatics
Change Healthcare
Adjunct Professor of Medicine
Duke University School of Medicine

7:15 a.m. – 7:55 a.m.

Registration/ Breakfast

7:55 a.m. – 8:00 a.m.

Welcome

Afreen Shariff, MD, MBBS

8:00 a.m. – 8:50 a.m.

Keynote Address: Immune Mediated Toxicities: The Past, Present and the Future
Kerry Reynolds, MD

8:50 a.m. – 9:30 a.m.

Endocrine Adverse Events
Afreen Shariff, MD, MBBS

9:30 a.m. – 9:50 a.m.

Renal Adverse Events
David Ortiz-Melo, MD

9:50 a.m. – 10:30 a.m.

Break and Exhibitor Showcase

10:30 a.m. – 11:10 a.m.

Gastrointestinal Adverse Events
Michael Dougan, MD, PhD

11:10 a.m. – 11:40 a.m.

Rheumatologic Adverse Events
Sophia Weinmann, MD

11:40 a.m. – 12:10 p.m.

Dermatologic Adverse Events
Meenal Kheterpal, MD

12:10 p.m. – 12:55 p.m.

Lunch

1:00 p.m. – 1:30 p.m.

Cardiac Adverse Events
Michel Khouri, MD

1:30 p.m. – 2:00 p.m.

Neuromuscular Adverse Events
Suma Shah, MD

2:00 p.m. – 2:30 p.m.

Break and Exhibitor Showcase

2:40 p.m. – 3:20 p.m.

Pulmonary Adverse Events
Momen Wahidi, MD

3:20 p.m. – 4:30 p.m.

Panel Discussion: Rethinking Toxicity Management

Afreen Shariff, MD, MBBS
Featuring: Michel Khouri, MD; Jon McDunn, PhD;
David Ortiz-Melo, MD; Kerry Reynolds, MD; Yousuf Zafar, MD

4:30 p.m. – 4:35 p.m.

Closing Remarks